拜玛林制药(BMRN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BMRN 拜玛林制药

盘后交易 04-23 19:10:25 EDT

61.94

+0.44

+0.72%

盘后61.94

+0.000.00%

16:41 EDT

最高63.39	最低61.63	成交量129.42万
今开62.16	昨收61.50	日振幅2.86%
总市值118.77亿	流通市值111.24亿	总股本1.92亿
成交额8,064万	换手率0.72%	流通股本1.80亿
市净率2.10	ROE8.05%	每股收益2.21
52周最高94.85	52周最低52.93	市盈率28.06
股息0.00	股息收益率0.00	ROA5.15%

北京优虎网络科技有限公司

{"stockData":{"symbol":"BMRN","market":"US","secType":"STK","nameCN":"拜玛林制药","latestPrice":61.94,"timestamp":1745438400000,"preClose":61.5,"halted":0,"volume":1294185,"hourTrading":{"tag":"盘后","latestPrice":61.94,"preClose":61.94,"latestTime":"16:41 EDT","volume":95606,"amount":5921836.59606,"timestamp":1745440911202},"delay":0,"floatShares":179589016,"shares":191754170,"eps":2.207261,"marketStatus":"盘后交易","change":0.44,"latestTime":"04-23 19:10:23 EDT","open":62.16,"high":63.39,"low":61.63,"amount":80640180.73644,"amplitude":0.028618,"askPrice":63.5,"askSize":100,"bidPrice":56.13,"bidSize":1,"shortable":3,"etf":0,"ttmEps":2.207261,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1745452800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":932702400000,"exchange":"NASDAQ","adjPreClose":61.5,"preHourTrading":{"tag":"盘前","latestPrice":62.12,"preClose":61.5,"latestTime":"09:29 EDT","volume":374,"amount":23334.299076,"timestamp":1745414999999},"postHourTrading":{"tag":"盘后","latestPrice":61.94,"preClose":61.94,"latestTime":"16:41 EDT","volume":95606,"amount":5921836.59606,"timestamp":1745440911202},"volumeRatio":0.602593,"impliedVol":0.4476,"impliedVolPercentile":0.944},"requestUrl":"/m/hq/s/BMRN","defaultTab":"news","newsList":[{"id":"2527146331","title":"拜玛林制药盘中异动 股价大涨5.00%报59.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527146331","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527146331?lang=zh_cn&edition=full","pubTime":"2025-04-15 03:54","pubTimestamp":1744660447,"startTime":"0","endTime":"0","summary":"北京时间2025年04月15日03时54分，拜玛林制药股票出现波动，股价快速拉升5.00%。截至发稿，该股报59.66美元/股，成交量108.409万股，换手率0.57%，振幅3.98%。拜玛林制药股票所在的生物技术行业中，整体涨幅为2.80%。拜玛林制药公司简介：拜玛林专注于是罕见病疗法。拜玛林还销售治疗罕见代谢性疾病PKU的Kuvan和Palynziq。拜玛林的 Roctavian于 2022 年在欧洲获批，2023 年在美国获批。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041503540794d54363&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041503540794d54363&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IE00B19Z3B42.SGD","BMRN","BK4566","IE00B7SZLL34.SGD","IE00B19Z3581.USD","IE0002270589.USD"],"gpt_icon":0},{"id":"2513372995","title":"奥本海默：上调Biomarin Pharmaceutical(BMRN.US)评级，由Perform调整至优于大市评级, 目标价98.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513372995","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513372995?lang=zh_cn&edition=full","pubTime":"2025-02-24 21:17","pubTimestamp":1740403022,"startTime":"0","endTime":"0","summary":"奥本海默：上调Biomarin Pharmaceutical(BMRN.US)评级，由Perform调整至优于大市评级, 目标价98.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/24211748352370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BMRN"],"gpt_icon":0},{"id":"1111972741","title":"异动解读 | 财报远超预期,拜玛林制药盘前大涨10.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=1111972741","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111972741?lang=zh_cn&edition=full","pubTime":"2025-02-20 18:18","pubTimestamp":1740046705,"startTime":"0","endTime":"0","summary":"2025年第四季度财报出炉,拜玛林制药公司大幅超过了市场预期,这一利好消息推动公司股价在今日盘前大涨10.52%。\n\n拜玛林制药此前公布的2025年第四季度每股收益为0.92美元,远高于市场预期的0.53美元;季度销售额也创下7.4731亿美元的新高。此番罕见的业绩喜讯,令投资者看好公司进一步发展前景。\n\n作为领先的罕见疾病专业制药企业,拜玛林制药的出色表现得益于其管线和产品创新所带来的增长。投资界普遍认为,在需求不断增长的罕见疾病领域,公司将凭借领先优势开发新药并扩大收入来源,高速增长将延续。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BMRN"],"gpt_icon":0},{"id":"1119520793","title":"异动解读 | 财报超预期利好发酵,拜玛林制药夜盘大涨9.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=1119520793","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119520793?lang=zh_cn&edition=full","pubTime":"2025-02-20 09:28","pubTimestamp":1740014916,"startTime":"0","endTime":"0","summary":"拜玛林制药公司在上周三夜盘交易中股价大涨9.72%,引发了投资者的广泛关注。股价暴涨的主要原因源自公司当季财报出现亮眼业绩,远超市场预期。拜玛林制药在2025年第四季度的每股收益和销售额均创下新高,分别达到0.92美元和7.4731亿美元,远高于分析师预期的0.53美元和7.1344亿美元。市场分析认为,在罕见疾病领域需求庞大的背景下,拜玛林制药凭借其领先优势,有望进一步开发新型疗法并扩大收入来源。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BMRN"],"gpt_icon":0},{"id":"1140129158","title":"异动解读 | 拜玛林制药盘后大涨7.83%,财报靓丽超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1140129158","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140129158?lang=zh_cn&edition=full","pubTime":"2025-02-20 05:33","pubTimestamp":1740000809,"startTime":"0","endTime":"0","summary":"拜玛林制药(BMRN)在周三的盘后交易中股价大涨7.83%,引发市场关注。\n\n盘后财报显示,拜玛林制药第四季度每股收益为0.92美元,远高于分析师预期的0.53美元。公司当季销售额也优于预期,达到7.4731亿美元,同比增长15.65%。由于业绩表现出色,公司股价在盘后呈现大涨态势。\n\n作为领先的罕见疾病治疗公司,拜玛林制药正努力扩大管线产品组合,并积极开拓新的疗法领域。这或许也为公司后续的业绩表现奠定基础。总体来看,本次财报利好消息的推动下,投资者对公司未来发展前景信心倍增,从而刺激股价出现明显上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BMRN"],"gpt_icon":0},{"id":"1142137647","title":"BioMarin制药第四季度调整后每股收益$0.92，超过预期的$0.53，销售额$7.4731亿，超出预期的$7.1344亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1142137647","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142137647?lang=zh_cn&edition=full","pubTime":"2025-02-20 05:08","pubTimestamp":1739999334,"startTime":"0","endTime":"0","summary":"公司报告季度销售额为$7.4731亿，超过分析师普遍预期的$7.1344亿，高出4.75%。以上内容来自Benzinga Earnings专栏，原文如下：Biomarin Pharmaceutical  reported quarterly earnings of $0.92 per share which beat the analyst consensus estimate of $0.53 by 73.58 percent. This is a 87.76 percent increase over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $747.31 million which beat the analyst consensus estimate of $713.44 million by 4.75 percent. This is a 15.65 percent increase over sales of $64","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"BioMarin制药第四季度调整后每股收益$0.92，超过预期的$0.53，销售额$7.4731亿，超出预期的$7.1344亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMRN"],"gpt_icon":0},{"id":"2504449484","title":"特朗普2.0时代即将开启，投资机会如何掘金？","url":"https://stock-news.laohu8.com/highlight/detail?id=2504449484","media":"招商基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504449484?lang=zh_cn&edition=full","pubTime":"2025-01-20 10:36","pubTimestamp":1737340585,"startTime":"0","endTime":"0","summary":"美国候任总统唐纳德·特朗普将于美东时间1月20日12时正式宣誓就任美国第47任总统。特朗普2.0时代即将开启，有哪些投资机会可以布局？值得一提的是，科技股在特朗普任期内表现尤为突出，成为推动美股上涨的主要力量。在特朗普第一个任期内，美元整体表现相对弱势。4年任期内，美元指数累计下跌了10.53%。而纵观全球市场，在特朗普上一任期内，恒生科技指数涨幅超过147%，表现甚至略微优于纳斯达克指数。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120103318abb12e8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120103318abb12e8e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ARM","QLD","NWSA","FAST","DSGX","FTNT","CHTR","NICE","LU0757428866.USD","CINF","ENPH","GEN","NTNX","PNFP","QCOM","AAPL","ROKU","SNPS","ALNY","GOOGL","ZS","GRAB","HQY","MEDP","SEIC","LIN","FRPT","AMAT","EWBC","QXO","TW","WWD","WBA","BKNG","GTLB","HOOD","RGLD","BK4588","BSY","GILD","NBIX","SFM","NFLX","TLN","BK4585","EXAS","CME","BK4581","CSCO","AMD","COKE","ITCI","JD","SSNC","AXON","JBHT","ESLT","MMYT","NVIW.SI","REG","ONC","ASML","FOXA","COIN","RYAAY","FSLR","ULTA","BK4550","LPLA","JKHY","OLED","DKNG","AMGN","NTRS",".IXIC","FTAI","TEAM","ORLY","MSFT","SQQQ","LU1815336091.USD","AVGO","LKQ","ANSS","BK4534","DLTR","EA","TROW","INTC","LNW","TPG","AGNC","CTSH","LU0053671581.USD","MANH","AKAM","PLTR","PSQ","TQQQ","ZM","LECO","EBAY","TTD","TSYW.SI","TER","STLD","SBUX","TMUS","DOX","MPWR","ISRG","PARA","CPRT","PAYX","USAW.SI","AAL","CSWI","BIIB","HON","INSM","FYBR","CDW","TSEM","CWST","HLNE","SOFI","PAA","HST","ICLR","KDP","AUR","Z","NXPI","CSX","EXE","SWKS","CHRW","LOGI","AMZN","WYNN","SIRI","LU2065731478.USD","ALGN","AFRM","AZN","EXPE","MTCH","ODFL","CSGP","ERIE","PCVX","QRVO","CYBR","RADX","RIVN","ROIV","GMAB","PTC","TCOM","FER","LSTR","DUOL","AEP","QQQ","AAON","EVRG","MDB","TECH","TTEK","ADSK","ARGX","GEHC","REGN","DDOG","NDAQ","NTES","NTAP","DASH","KHC","FWONK","EQIX","MNDY","FSV","CASY","RGEN","LI","PCAR","RPRX","LNT","ERIC","MDLZ","MNST","LAMR","INTU","CTAS","FOX","MTSI","BPMC","SBAC","NTRA","CCEP","BKR","BRKR","RKLB","CFLT","SAIA","BK4086","MKTX","USJW.SI","WDC","BPOP","TSCO","HOLX","ALAB","INCY","LULU","META","CHDN","DPZ","ON","STX","WTFC","MRNA","CPB","ENTG","GLPI","LSCC","NDSN","MIDD","FCNCA","TSLA","CHRD","COO","HBAN","NVMI","MKSI","PFG","PEP","MCHP","NQmain","BMRN","CBSH","IDXX","MNQmain","PCTY","ROST","CHKP","PDD","CZR","MARA","TTWO","TRMB","MRVL","FFIV","ILMN","APA","PODD","CEG","QID","ROP","TXN","CRWD","COST","HTHT","OKTA","ADBE","HSIC","SMCI","MELI","CG","BK4593","CDNS","POOL","RVMD","NVDA","GNTX","SRPT","DOCU","ADI","BK4561","OTEX"],"gpt_icon":1},{"id":"2503689242","title":"拜玛林制药盘中异动 临近收盘股价大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503689242","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503689242?lang=zh_cn&edition=full","pubTime":"2025-01-15 04:47","pubTimestamp":1736887645,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日04时47分，拜玛林制药股票出现异动，股价大幅跳水5.04%。截至发稿，该股报63.62美元/股，成交量115.596万股，换手率0.61%，振幅5.55%。拜玛林制药股票所在的生物技术行业中，整体跌幅为1.34%。拜玛林制药公司简介：拜玛林专注于是罕见病疗法。Genzyme公司通过与拜玛林公司的合资企业销售Aldurazyme，拜玛林公司则独立销售Naglazyme，Vimizim和Brineura。拜玛林还销售治疗罕见代谢性疾病PKU的Kuvan和Palynziq。拜玛林的 Roctavian于 2022 年在欧洲获批，2023 年在美国获批。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501150447269603ba7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501150447269603ba7b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BMRN","IE0002270589.USD","IE00B19Z3581.USD","BK4139","IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","BK4566"],"gpt_icon":0},{"id":"2489411799","title":"拜玛林制药盘中异动 急速上涨5.05%报66.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2489411799","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489411799?lang=zh_cn&edition=full","pubTime":"2024-12-05 01:28","pubTimestamp":1733333325,"startTime":"0","endTime":"0","summary":"北京时间2024年12月05日01时28分，拜玛林制药股票出现异动，股价急速上涨5.05%。截至发稿，该股报66.38美元/股，成交量121.89万股，换手率0.64%，振幅5.53%。拜玛林制药股票所在的生物技术行业中，整体涨幅为0.46%。拜玛林制药公司简介：拜玛林专注于是罕见病疗法。拜玛林还销售治疗罕见代谢性疾病PKU的Kuvan和Palynziq。拜玛林的 Roctavian于 2022 年在欧洲获批，2023 年在美国获批。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120501284598e56490&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120501284598e56490&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B19Z3B42.SGD","IE00B19Z3581.USD","BK4139","BK4566","BMRN","IE0002270589.USD","IE00B7SZLL34.SGD"],"gpt_icon":0},{"id":"2480730058","title":"拜玛林制药2024财年第三财季实现净利润1.06亿美元，同比增加162.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480730058","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480730058?lang=zh_cn&edition=full","pubTime":"2024-11-03 00:00","pubTimestamp":1730563252,"startTime":"0","endTime":"0","summary":"11月3日，拜玛林制药公布财报，公告显示公司2024财年第三财季净利润为1.06亿美元，同比增加162.51%；其中营业收入为7.42亿美元，同比增加26.62%，每股基本收益为0.56美元。从资产负债表来看，拜玛林制药总负债14.38亿美元，其中短期债务0.00美元，资产负债比为4.77，流动比率为4.27。机构评级：截至2024年11月3日，当前有25家机构对拜玛林制药目标价做出预测，其中目标均价为96.72美元，其中最低目标价为65.00美元，最高目标价为127.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241103000111a20f7af3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241103000111a20f7af3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BMRN"],"gpt_icon":0},{"id":"1159145068","title":"异动解读 | 拜玛林制药公司领跌生物科技股 公司业绩超预期但长期前景受质疑","url":"https://stock-news.laohu8.com/highlight/detail?id=1159145068","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159145068?lang=zh_cn&edition=full","pubTime":"2024-10-30 21:36","pubTimestamp":1730295368,"startTime":"0","endTime":"0","summary":"拜玛林制药(BMRN)今日盘中大跌5.21%,引发市场广泛关注。尽管公司刚刚公布的上一季度业绩超出预期,但分析师对公司长期增长前景下调评级和目标价,成为拖累该股走低的主要原因。\n\n根据财报显示,拜玛林制药上季每股收益为0.55美元,高于分析师预期的0.52美元。营收同比增长28.3%至7.46亿美元,也超过了分析师的预期。公司旗舰产品在多个治疗领域表现出色,拉动了业绩增长。\n\n但与此同时,多家分析机构对公司的长期增长前景表示质疑。路透数据显示,有分析师将该股目标价下调至105美元,另有分析师直接下调公司评级。市场忧虑公司核心药品未来销售可能放缓,且新产品线研发进展缓慢,长期发展动力不足。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BMRN"],"gpt_icon":0},{"id":"2479834477","title":"拜玛林制药盘中异动 大幅下挫5.21%报66.27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479834477","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479834477?lang=zh_cn&edition=full","pubTime":"2024-10-30 21:31","pubTimestamp":1730295076,"startTime":"0","endTime":"0","summary":"北京时间2024年10月30日21时31分，拜玛林制药股票出现波动，股价大幅下挫5.21%。截至发稿，该股报66.27美元/股，成交量4.0672万股，换手率0.02%，振幅0.52%。拜玛林制药股票所在的生物技术行业中，整体跌幅为0.30%。拜玛林制药公司简介：拜玛林专注于是罕见病疗法。拜玛林还销售治疗罕见代谢性疾病PKU的Kuvan和Palynziq。拜玛林的 Roctavian于 2022 年在欧洲获批，2023 年在美国获批。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030213117a1face5f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030213117a1face5f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B7SZLL34.SGD","IE0002270589.USD","IE00B19Z3B42.SGD","IE00B19Z3581.USD","BK4139","BK4566","BMRN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bmrn.com","stockEarnings":[{"period":"1week","weight":0.0247},{"period":"1month","weight":-0.1367},{"period":"3month","weight":-0.0084},{"period":"6month","weight":-0.1263},{"period":"1year","weight":-0.3128},{"period":"ytd","weight":-0.0644}],"compareEarnings":[{"period":"1week","weight":-0.0193},{"period":"1month","weight":-0.0651},{"period":"3month","weight":-0.1306},{"period":"6month","weight":-0.0898},{"period":"1year","weight":0.0551},{"period":"ytd","weight":-0.1004}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Biomarin Pharmaceutical Inc.于1996年10月在特拉华州注册成立，并于1997年3月21日开始运营。该公司是一家全球性生物技术公司，致力于将基因发现的前景转化为对每位患者的生活产生深远影响的药物。T. BioMarin为代表重大未满足医疗需求的疾病和病症选择候选产品，这些疾病和病症具有很好的生物学理解，并提供了率先上市或提供优于现有产品的机会。该公司的产品组合由四个已获批准的产品和多个研究候选产品组成。","yearOnYearQuotes":[{"month":1,"riseRate":0.653846,"avgChangeRate":0.049688},{"month":2,"riseRate":0.461538,"avgChangeRate":0.013226},{"month":3,"riseRate":0.461538,"avgChangeRate":0.004784},{"month":4,"riseRate":0.5,"avgChangeRate":-0.020069},{"month":5,"riseRate":0.52,"avgChangeRate":0.009961},{"month":6,"riseRate":0.64,"avgChangeRate":0.01979},{"month":7,"riseRate":0.64,"avgChangeRate":0.039011},{"month":8,"riseRate":0.538462,"avgChangeRate":0.00179},{"month":9,"riseRate":0.461538,"avgChangeRate":-0.010547},{"month":10,"riseRate":0.423077,"avgChangeRate":-0.02699},{"month":11,"riseRate":0.807692,"avgChangeRate":0.061906},{"month":12,"riseRate":0.615385,"avgChangeRate":0.033466}],"exchange":"NASDAQ","name":"拜玛林制药","nameEN":"Biomarin Pharmaceutical"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"拜玛林制药(BMRN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供拜玛林制药(BMRN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"拜玛林制药,BMRN,拜玛林制药股票,拜玛林制药股票老虎,拜玛林制药股票老虎国际,拜玛林制药行情,拜玛林制药股票行情,拜玛林制药股价,拜玛林制药股市,拜玛林制药股票价格,拜玛林制药股票交易,拜玛林制药股票购买,拜玛林制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"拜玛林制药(BMRN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供拜玛林制药(BMRN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}